More serious issues than the name change, page-77

First 77 Last

Share
Profile

Follow
hottod

6,390 Posts.

23386

09/05/15

11:44

Post #: 15247267
Share

Originally posted by Southoz ↑

“...if that evidence existed we would be at 3c? So without phase 3 results know one can make a judgement on potential?”

Its an interesting way of looking at it GC. I think the idea is that everything builds from the ground up.

With a product having to pass increasingly difficult tests during its development. And your confidence is based n how easily it cleared those earlier tests.

But for POH I think the problem has been they are so slow those goal-posts have shifted over time. And its not until recently that it has become clearer what exactly is required. How high is the bar.

The lack of papers seem to me to be a symptom. Papers report science experiments . We tried this, it may or may not have worked, but guess what it did. And it wasn’t due to chance (p<0.05).

Null hypothesis testing is all about binary outcomes.

But binary outcomes have been an anathema to Rosen and Ogru. After some spectacular crashes with the obesity drug in the early days (Ogru) and then jointly with Nestle.

The consequence of avoiding binary outcomes is no papers.

POH became like the student that chooses continuously assessed subjects to avoid exams. And handed up pretty share holder pr updates for assessment for years and kind of passed.

But a few months ago POH met with the exam kings of the world – the FDA. Binary outcome central.

POH report that more trials are required, they are challenging and not without risk. Yep ... well hello ... thats what exams are like.

Is the student up to it? Well the market halved the share price.

I have a half a notion the new Board is less about getting the old to work and more about working out what the new will be.

The answer to this doesn’t just fall out of the sky – the technology needs clever matching to a problem. Which is a very different way of looking at the technology as a solution in search of a problem.

So its not steady as she goes. Hire a CRO, negotiate a contract, sit back and wait for the results of the US P2 oxym to roll in.

My guess is the systemic oxym patch will get the chop, and never make it to the IND starting gate. The clever guys on the new Board will conjure up some new ideas and with money in bank away it all goes again.

But we shall see.

Expand

But a few months ago POH met with the exam kings of the world – the FDA. Binary outcome central.

POH report that more trials are required, they are challenging and not without risk. Yep ... well hello ... thats what exams are like.

Is the student up to it? Well the market halved the share price.

Hi Southoz

As per my previous request on this thread (07/05), could you please provide supporting evidence.

POH Price at posting: 3.1¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

OVT

Nearly a year later, Ovanti revives Nasdaq talks after a BNPL revival in the US

SLX

SILEX eyeing one-year breakeven as latest uranium uptick supports updates on enrichment testing

Listen: HotCopper Wire Podcast 025 – Locksley rap video gives Hilltop Hoods run for money

Market Close: The US Fed rate is one thing – but are FDI outflows bringing down a boring ASX in favour of Wall Street?

PCK

Painchek sees modest gain on reports aged care monitoring app bodes well in Scottish pilot

First 77 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.7¢		Change 0.001(7.69%)		Mkt cap ! $22.21M

Open	High	Low	Value	Volume
0.7¢	0.8¢	0.7¢	$12.71K	1.806M

Buyers (Bids)

No.	Vol.	Price($)
7	6226559	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	7857997	15

View Market Depth

No.	Vol.	Price($)
6	5226559	0.007
30	20985937	0.006
21	12579758	0.005
19	12120585	0.004
17	10813335	0.003

Price($)	Vol.	No.
0.008	7857997	15
0.009	8947560	12
0.010	2254192	10
0.011	4450000	2
0.012	5271926	7

Last trade - 16.10pm 17/09/2025 (20 minute delay)

AVE (ASX) Chart

More serious issues than the name change, page-77

Nearly a year later, Ovanti revives Nasdaq talks after a BNPL revival in the US

SILEX eyeing one-year breakeven as latest uranium uptick supports updates on enrichment testing

Listen: HotCopper Wire Podcast 025 – Locksley rap video gives Hilltop Hoods run for money

Market Close: The US Fed rate is one thing – but are FDI outflows bringing down a boring ASX in favour of Wall Street?

Painchek sees modest gain on reports aged care monitoring app bodes well in Scottish pilot

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

More serious issues than the name change, page-77

Top Stories

Nearly a year later, Ovanti revives Nasdaq talks after a BNPL revival in the US

SILEX eyeing one-year breakeven as latest uranium uptick supports updates on enrichment testing

Listen: HotCopper Wire Podcast 025 – Locksley rap video gives Hilltop Hoods run for money

Market Close: The US Fed rate is one thing – but are FDI outflows bringing down a boring ASX in favour of Wall Street?

Painchek sees modest gain on reports aged care monitoring app bodes well in Scottish pilot

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News